The short answer: one treatment versus ongoing cycles

The difference between ChondroFiller™ and most other knee injections is not simply how long each one lasts — it is what each one is trying to do.

ChondroFiller™ is designed as a single-course injectable collagen scaffold. Rather than topping up symptoms every few months, it aims to provide a structure into which the body's own cells can migrate and produce new cartilage tissue. Published data indicate the scaffold is progressively resorbed over one to two years, replaced by the patient's own repair tissue — meaning the intention is a lasting biological fix at the defect site, not a temporary measure.

By contrast, hyaluronic acid (HA) injections lubricate the joint and typically require a repeat course roughly every six months. Corticosteroids can reduce inflammation quickly but their effect generally fades within weeks to a few months, and frequent repeat use is not advisable. Arthrosamid® sits in a different category again: a non-biodegradable hydrogel that remains in the joint permanently as a mechanical cushion — long-lasting, but via padding rather than repair. The sections below examine the clinical evidence behind each of these timelines.

ChondroFiller's repair timeline: what happens and when

Four broad stages define how ChondroFiller™ works — and why its durability story is fundamentally different from anything that simply lubricates or cushions the joint.

Stage 1 — the scaffold sets immediately. Once the collagen gel is placed at the defect site during an ultrasound-guided outpatient procedure, it hardens in approximately three to five minutes, forming a dimensionally stable matrix that sits within the cartilage lesion.

Stage 2 — your own cells move in. Over the days and weeks that follow, the body's cartilage-forming cells begin migrating into the scaffold. This is not theoretical: a 2025 ex vivo study measured a 2.4-fold increase in DNA content within the scaffold by day 14, providing direct mechanistic evidence of active host cell infiltration.

Stage 3 — symptoms begin to ease. Functional improvement typically starts at around six to twelve weeks post-treatment, with continued gains building across the first year. This gradual onset reflects the time it takes for the migrating cells to mature and begin producing repair tissue — rather than the near-immediate (but short-lived) relief that lubricating or anti-inflammatory injections can provide.

Stage 4 — the scaffold is replaced by the patient's own tissue. As new cartilage matures within the defect, the collagen matrix is gradually resorbed. Published data indicate this resorption and replacement process is largely complete within one to two years — leaving the patient's own repair tissue where the scaffold once was.

This staging matters because it explains why clinical improvement accumulates slowly rather than arriving in days, and why the treatment is designed as a single course rather than an ongoing cycle.

How long hyaluronic acid lasts — and what it actually does

Hyaluronic acid works by replenishing the joint's natural lubricating fluid — a process called viscosupplementation. Introducing a gel-like solution into the joint space restores or augments the viscosity of synovial fluid, which reduces friction during movement and can ease pain and stiffness in the short to medium term. The mechanism is physical rather than biological: HA does not prompt cell migration, fill a structural void, or produce new cartilage tissue.

The clinical effect from each treatment course typically lasts around six months, after which most patients who respond well can repeat the injection series. Published evidence does not flag a safety concern with ongoing long-term repeat use — a meaningful distinction from corticosteroids, where frequent repeat dosing raises additional considerations. Course protocols generally involve one to five injections given at weekly intervals, though studies have not consistently shown a five-injection course to be superior to a shorter three-injection one.

For patients with diffuse, mild-to-moderate osteoarthritis where the priority is symptom management, HA offers a well-established, repeatable option. For an isolated, focal cartilage defect — the scenario ChondroFiller™ targets — the structural question that HA leaves unanswered becomes more significant. These are genuinely different clinical contexts that call for different approaches rather than variations on the same solution.

Other injection options and how long their effects last

Three further injection categories complete the picture, each with a distinct mechanism and a different relationship with time.

Corticosteroids act quickly — typically within days — by reducing intra-articular inflammation. The effect can ease acute pain and stiffness, but for most patients it lasts only a few weeks to a few months. Because repeat dosing raises concerns about cumulative effects on joint tissues, corticosteroid injections are generally used for short-term relief or to manage inflammation ahead of another intervention rather than as an ongoing strategy.

Arthrosamid® (polyacrylamide hydrogel) is non-biodegradable and designed to remain in the joint permanently as a mechanical cushion. Because it is not resorbed, published literature describes it as among the longer-lasting of the symptom-modifying injection options. Integration into the joint lining requires approximately 14 days of relative rest post-injection. The mechanism is physical load-sharing — padding rather than tissue change.

nSTRIDE® is an autologous protein solution prepared from concentrated blood. Some published series report that its benefits — principally pain reduction and reduced inflammation — can be sustained up to three years from a single injection, giving it the longest documented duration among symptom-relief preparations in this group.

PRP and biologic options (including microfragmented adipose tissue and bone marrow concentrate) show variable results across trials. Leucocyte-poor PRP preparations, for example, have been associated in some published series with symptomatic benefit lasting approximately six to twelve months from a single course, though outcomes differ markedly by preparation protocol, platelet concentration, and patient profile. The evidence base across this category continues to mature and no single standard protocol has yet emerged.

What the clinical evidence shows about ChondroFiller's durability

The majority of published studies are manufacturer-sponsored or drawn from small European cohorts — a genuine limitation worth naming before the numbers. With that context, the available data point consistently in the same direction.

The strongest durability evidence comes from a post-market clinical follow-up study by Jerosch et al., which tracked patients over three years. Mean IKDC scores — a validated patient-reported measure of knee function — improved by approximately 32 points from baseline, reaching a functional score of 80. That improvement exceeded the established minimal clinically important difference of 16.7 points, and was sustained and marginally increased at the three-year mark rather than declining. MRI-based MOCART scores in the same study ranged from 81.6 to 84.3, reflecting greater than 80% structural defect filling and good integration with the surrounding native cartilage. Progressive maturation was visible: imaging scores improved from 65.3 at four weeks to 81.6 at one year, consistent with the biological timeline described earlier in this article.

A 2016 randomised multicentre trial reported statistically significant IKDC improvements at three months and six months that were maintained at twelve-month follow-up, with no adverse events recorded. A 2024 cohort study of 17 younger patients (mean age 31) found significant improvements in both IKDC and Lysholm scores at three, six, and twelve months. Notably, no statistically significant difference was found between the six- and twelve-month values, suggesting that the bulk of functional recovery is established within six months — though the scaffold continues resorbing beyond that point.

Published success rates vary across studies, but comparisons across those figures are difficult because the methodological definitions differ. No large, independent, long-term randomised controlled trial is yet available. How well any individual patient does in practice depends on defect size and depth, the health of the surrounding cartilage, and how closely post-treatment rehabilitation is followed — factors explored in the next section.

What affects whether ChondroFiller works — and for how long

Several factors shape how well the scaffold integrates — and how durable the benefit proves in practice.

Defect size and depth play a central role. Smaller, well-defined focal lesions give the scaffold the best conditions for complete cell colonisation; larger defects present a greater volume for migrating cells to fill, and outcomes may reflect that difference.

The surrounding cartilage is the cell source. ChondroFiller relies on adjacent native tissue to supply chondrocytes that migrate into the matrix. Where surrounding cartilage is healthy, that migration is well-supported; where it is significantly degraded, the scaffold has less to draw from.

Rehabilitation adherence matters. Clinical series — including the Jerosch et al. three-year follow-up and a 2024 cohort of 17 younger patients — consistently note that protecting the joint during the active repair phase is important for achieving full integration. Loading the joint too early risks disrupting the matrix before new tissue has consolidated.

Patient selection is the central variable. ChondroFiller is designed for focal cartilage defects in otherwise reasonable joint condition — not for diffuse whole-joint osteoarthritis. Where degeneration is widespread, the scaffold addresses only part of the picture, and an alternative or combined treatment pathway may be more appropriate.

In short, patients with a contained focal defect and healthy surrounding tissue represent the population in whom published evidence suggests a durable, single-course outcome is achievable — while those with advanced whole-joint disease may not be suitable candidates at all. An eligibility review at amsk.co.uk can help determine whether the treatment pathway fits your specific defect and joint condition.

1. [1] Implantation of ChondroFiller Liquid® as a Scaffold Material for the Treatment of Chondral Lesions of the Knee Joint. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
2. [2] Controlled, randomized multicenter study to compare compatibility and safety of ChondroFiller liquid with microfracturing of patients with focal cartilage defects of the knee joint. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
3. [3] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759